BAJAJ BROKING

open-demat-imgOpen Demat
Login-imgLoginopens in a new tab
be-a-partner-imgBe a Partner
samadhan-imgSamadhanopens in a new tab
open-demat-imgOpen Demat
InstallInstall App
Download AppInstall App
Notification
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

4410

507789

JAGSNPHARM

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Jagsonpal Pharmaceuticals Performance

Today’s low

Today’s high

₹ 207.40 ₹ 225.47
₹ 212.15

52 week low

52 week high

₹ 110.00 ₹ 328.04
₹ 212.15

Open Price

₹ 221.58

Prev. Close

₹ 219.82

Volume (Shares)

170091.00

Total traded value

₹ 360.84

Upper Circuit

₹ 263.78

Lower Circuit

₹ 175.85

info

Jagsonpal Pharmaceuticals Share Price Update

As of the latest trading session, Jagsonpal Pharmaceuticals share price is currently at ₹ 208.9, which is down by ₹ -10.92 from its previous closing. Today, the stock has fluctuated between ₹ 207.40 and ₹ 225.47. Over the past year, Jagsonpal Pharmaceuticals has achieved a return of 67.82 %. In the last month alone, the return has been 8.34 %. Read More...

Jagsonpal Pharmaceuticals Fundamentals


  • Market cap (Cr)

    1,411.40

  • P/E Ratio (TTM)

    27.93

  • Beta

    1.70

  • Book Value / share

    29.69

  • Return on equity

    12.97%

  • EPS (TTM)

    5.49

  • Dividend yield

    1.14%

  • Net profit/quarter (Cr)

    6.58

info icon alternate text

Jagsonpal Pharmaceuticals Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars MAR 2025 (Values in Cr)
Revenue 58.56
Operating Expense 52.41
Net Profit 6.58
Net Profit Margin (%) 11.23
Earnings Per Share (EPS) 0.98
EBITDA 11.28
Effective Tax Rate (%) 24.45
Particulars DEC 2024 (Values in Cr)
Revenue 74.03
Operating Expense 60.86
Net Profit 31.99
Net Profit Margin (%) 43.21
Earnings Per Share (EPS) 4.74
EBITDA 41.34
Effective Tax Rate (%) 17.27
Particulars SEP 2024 (Values in Cr)
Revenue 74.69
Operating Expense 60.98
Net Profit 11.46
Net Profit Margin (%) 15.34
Earnings Per Share (EPS) 4.29
EBITDA 17.93
Effective Tax Rate (%) 25.43
Particulars JUN 2024 (Values in Cr)
Revenue 61.44
Operating Expense 52.49
Net Profit 5.33
Net Profit Margin (%) 8.67
Earnings Per Share (EPS) 1.94
EBITDA 8.40
Effective Tax Rate (%) 25.03
Particulars MAR 2024 (Values in Cr)
Revenue 43.49
Operating Expense 41.44
Net Profit 3.55
Net Profit Margin (%) 8.16
Earnings Per Share (EPS) 1.31
EBITDA 5.16
Effective Tax Rate (%) 21.80
Particulars MAR 2025 (Values in Cr)
Revenue 268.72
Operating Expense 226.74
Net Profit 55.36
Net Profit Margin (%) 20.60
Earnings Per Share (EPS) 8.26
EBITDA 78.94
Effective Tax Rate (%) 20.75
Particulars MAR 2024 (Values in Cr)
Revenue 208.70
Operating Expense 188.11
Net Profit 22.46
Net Profit Margin (%) 10.76
Earnings Per Share (EPS) 8.49
EBITDA 32.33
Effective Tax Rate (%) 24.80
Particulars MAR 2023 (Values in Cr)
Revenue 236.71
Operating Expense 204.18
Net Profit 26.72
Net Profit Margin (%) 11.28
Earnings Per Share (EPS) 10.20
EBITDA 36.43
Effective Tax Rate (%) 23.24
Particulars MAR 2022 (Values in Cr)
Revenue 217.58
Operating Expense 194.37
Net Profit 18.86
Net Profit Margin (%) 8.66
Earnings Per Share (EPS) 7.20
EBITDA 28.46
Effective Tax Rate (%) 29.24
Particulars MAR 2021 (Values in Cr)
Revenue 187.95
Operating Expense 170.45
Net Profit 17.06
Net Profit Margin (%) 9.07
Earnings Per Share (EPS) 6.51
EBITDA 23.47
Effective Tax Rate (%) 21.99
Particulars MAR 2024 (Values in Cr)
Book Value / Share 70.88
ROE % 12.97
ROCE % 16.89
Total Debt to Total Equity 0.04
EBITDA Margin 15.50
Particulars MAR 2023 (Values in Cr)
Book Value / Share 60.65
ROE % 18.32
ROCE % 23.48
Total Debt to Total Equity 0.02
EBITDA Margin 15.39
Particulars MAR 2022 (Values in Cr)
Book Value / Share 50.68
ROE % 15.28
ROCE % 21.14
Total Debt to Total Equity 0.03
EBITDA Margin 13.08
Particulars MAR 2021 (Values in Cr)
Book Value / Share 43.55
ROE % 15.70
ROCE % 19.57
Total Debt to Total Equity 0.05
EBITDA Margin 12.49
Particulars MAR 2020 (Values in Cr)
Book Value / Share 39.39
ROE % 7.88
ROCE % 9.53
Total Debt to Total Equity 0.04
EBITDA Margin 6.97
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 147.93
Total Assets 217.07
Total Liabilities 217.07
Total Equity 187.40
Share Outstanding 26437794
Price to Book Ratio 3.95
Return on Assets (%) 10.34
Return on Capital (%) 11.99
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 114.62
Total Assets 194.94
Total Liabilities 194.94
Total Equity 158.89
Share Outstanding 26198000
Price to Book Ratio 4.78
Return on Assets (%) 13.70
Return on Capital (%) 16.82
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 25.24
Total Assets 164.22
Total Liabilities 164.22
Total Equity 132.75
Share Outstanding 26198000
Price to Book Ratio 6.19
Return on Assets (%) 11.48
Return on Capital (%) 14.2
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 60.22
Total Assets 164.20
Total Liabilities 164.20
Total Equity 121.92
Share Outstanding 26198000
Price to Book Ratio 1.83
Return on Assets (%) 10.38
Return on Capital (%) 13.25
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 38.07
Total Assets 146.95
Total Liabilities 146.95
Total Equity 111.03
Share Outstanding 26198000
Price to Book Ratio 0.44
Return on Assets (%) 5.35
Return on Capital (%) 6.8
Particulars MAR 2024 (Values in Cr)
Net Income 29.86
Cash from Operations 43.67
Cash from Investing -24.54
Cash from Financing -8.91
Net change in Cash 1.70
Free Cash Flow 43.92
Particulars MAR 2023 (Values in Cr)
Net Income 34.80
Cash from Operations 53.93
Cash from Investing -57.67
Cash from Financing -0.45
Net change in Cash -11.47
Free Cash Flow 54.24
Particulars MAR 2022 (Values in Cr)
Net Income 26.64
Cash from Operations 13.78
Cash from Investing -25.77
Cash from Financing -17.55
Net change in Cash -36.41
Free Cash Flow 14.83
Particulars MAR 2021 (Values in Cr)
Net Income 21.87
Cash from Operations 31.37
Cash from Investing -2.26
Cash from Financing -6.82
Net change in Cash 19.12
Free Cash Flow 31.84
Particulars MAR 2020 (Values in Cr)
Net Income 9.41
Cash from Operations 12.81
Cash from Investing -10.76
Cash from Financing -0.94
Net change in Cash -0.46
Free Cash Flow 14.88

Jagsonpal Pharmaceuticals Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
212.60 -3.28 redarrow
red-green-graph indicator
14 Bearish
2 Bullish
  • 5 Days 232.30
  • 26 Days 226.60
  • 10 Days 231.60
  • 50 Days 225.30
  • 12 Days 230.80
  • 100 Days 223.30
  • 20 Days 228.00
  • 200 Days 210.10

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

Jagsonpal Pharmaceuticals Shareholding Pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
30.11%
Promoter Holdings
67.77%
FII
2.1%
DII
0.0%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Aresko Progressive Private Limited 1.3335635E7 (20.08%) Shareholding of Promoter and Promoter Group
Infinity Holdings Sidecar I 1.188825E7 (17.9%) Shareholding of Promoter and Promoter Group
Infinity Holdings 1.103255E7 (16.62%) Shareholding of Promoter and Promoter Group
Infinity Portfolio Holdings 5717950.0 (8.61%) Shareholding of Promoter and Promoter Group
Rajpal Singh Kochhar 3030400.0 (4.56%) Shareholding of Promoter and Promoter Group
Manish Gupta 1656512.0 (2.49%) Public Shareholding
Mukul Mahavir Agrawal 1157557.0 (1.74%) Public Shareholding
Authum Investment And Infrastructure Limited 967965.0 (1.46%) Public Shareholding
Sanjiv Kumar Dudeja 926360.0 (1.4%) Public Shareholding
Lincoln P Coelho 775500.0 (1.17%) Public Shareholding
Infinity Consumer Holdings 0.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Jagsonpal Pharmaceuticals Corporate Actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
21 Aug 2023 5.0 Final 21 Aug 2023 Equity shares
29 Oct 2021 4.0 Interim 01 Nov 2021 Equity shares
22 Sep 2021 1.0 Final 24 Sep 2021 Equity shares
22 Sep 2020 0.5 Final 24 Sep 2020 Equity shares
20 Sep 2019 0.25 Final 24 Sep 2019 Equity shares
18 Sep 2018 0.1 Final 21 Sep 2018 Equity shares
21 Sep 2017 0.1 Final 23 Sep 2017 Equity shares
21 Sep 2016 0.1 Final 23 Sep 2016 Equity shares
21 Sep 2015 0.1 Final 23 Sep 2015 Equity shares
25 Sep 2014 0.5 Final 27 Sep 2014 Equity shares
25 Sep 2013 0.5 Final 27 Sep 2013 Equity shares
21 Sep 2012 5.0 Final 25 Sep 2012 Equity shares
23 Sep 2011 0.5 Final 27 Sep 2011 Equity shares
21 Sep 2010 0.5 Final 23 Sep 2010 Equity shares
23 Sep 2009 0.25 Final 25 Sep 2009 Equity shares
24 Sep 2008 0.1 Final 26 Sep 2008 Equity shares
21 Sep 2007 0.1 Final 25 Sep 2007 Equity shares
26 Sep 2005 0.0 Final 28 Sep 2005 Equity shares

Jagsonpal Pharmaceuticals Share Price

Promoted by Rajpal Singh Kochhar in August, 1978, Jagsonpal Pharmaceuticals Limited is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The Company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously, it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd.

The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company.

Parent organization Indian Private
NSE symbol JAGSNPHARM
Founded 1978
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow

Manish Gupta

Managing Director

Harsha Raghavan

Chairman & Non Executive Dir.

Debasis Bikash Nandy

Independent Director

Radhika Dudhat

Independent Director

Pallavi Dinodia

Independent Director

Right Arrow

Similar stocks

Left Arrow
similar-logo CONCORDBIO
+9.05%
1523 +126.4
down-arrow
similar-logo SMSLIFE
+7.03%
1290.9 +84.8
down-arrow
similar-logo WALPAR
+4.91%
45.9 +2.15
down-arrow
similar-logo SOLARA
+3.85%
500 +18.54
down-arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The share price of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 208.9 and for BSE is ₹ 210.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The market cap of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 14,11.40 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd?

Answer Field

The 52 Week High and Low of Jagsonpal Pharmaceuticals Ltd for NSE is ₹ 328.04 and ₹ 110.00 and for BSE is ₹ 328.02 and ₹ 109.42.

How to Buy Jagsonpal Pharmaceuticals Ltd share?

Answer Field

You can trade in Jagsonpal Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Jagsonpal Pharmaceuticals Ltd?

Answer Field

The 1 year returns on the stock has been 67.82%.

What is the Current Share Price of Jagsonpal Pharmaceuticals Ltd?

Answer Field

Jagsonpal Pharmaceuticals Ltd share price is for NSE ₹ 208.9 & for BSE ₹ 210 as on May 08 2025 03:29 PM.

What is the Market Cap of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

The market cap of Jagsonpal Pharmaceuticals Ltd for NSE ₹ 14,11.40 & for BSE ₹ 0.0 as on May 08 2025 03:29 PM.

What is the P/E Ratio of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

As on May 08 2025 03:29 PM the price-to-earnings (PE) ratio for Jagsonpal Pharmaceuticals Ltd share is 27.93.

What is the PB ratio of Jagsonpal Pharmaceuticals Ltd Share?

Answer Field

As on May 08 2025 03:29 PM, the price-to-book (PB) ratio for Jagsonpal Pharmaceuticals Ltd share is 29.69.

How to Buy Jagsonpal Pharmaceuticals Ltd Share on Bajaj Broking App?

Answer Field

To buy Jagsonpal Pharmaceuticals Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Jagsonpal Pharmaceuticals Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

Related News & Articles

Open Demat Account
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

TRENDING CALCULATORS AND STOCKS ON BAJAJ BROKING

Popular Stock

top-popular-on-bfsl

POPULAR STOCKS: Tata Motors Share Price Infosys Share Price IRFC Share Price SBI Card Share Price Cipla Share Price NBCC Share Price IDFC First Bank Share Price IRCTC Share Price PNB Share Price Vodafone Idea Share Price Axis Bank Share Price JSW Steel Share Price Bandhan Bank Share Price SBI Share Price Tata Steel Share Price ONGC Share Price Ashok Leyland Share Price Paytm Share Price Subex Share Price DLF Share Price Reliance Share Price HDFC Bank Share Price Suzlon Share Price IOC Share Price HUL Share Price Asian Paints Share Price Bank Of Baroda Share Price ITC Share Price TCS Share Price HFCL Share Price Icici Bank Share Price Tata Chemicals Share Price CDSI Share Price MRF Share Price Tata Power Share Price Adani Green share price BPCL Share Price Vedanta Share Price Dmart Share Price Hindalco Share Price LIC Share Price SAIL Share Price Adani Port Share Price IEX Share Price Nalco Share Price L&T Share Price Adani Power Share Price BHEL Share Price Bajaj Finance Share Price Canara Bank Share Price Indusind Bank Share Price Gail Share Price Yes Bank Share Price Wipro Share Price Happiest Minds Share Price Coal India Share Price Maruti Share Price Reliance Power Share Price

 

INDIAN INDICES: Nifty 50 Share Price SENSEX Share Price Nifty Next 50 Share Price BSE100 Share Price Nifty Bank Share Price LRGCAP Share Price Nifty 100 Share Price MIDCAP Share Price Nifty 200 Share Price SMLCAP Share Price Nifty 500 Share Price BSE500 Share Price Nifty Midcap 50 Share Price ALLCAP Share Price NIFTY SMLCAP 50 Share Price BSE200 Share Price India VIX Share Price BSEIPO Share Price

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC...